The Global Immunoassay Market was valued at USD 30.02 billion in 2022 that is expected to reach a value of USD 27.5 billion by 2030, with a compound annual growth rate (CAGR) of 6.3% during the forecast period of 2020 to 2030. Immunoassays are a class of analytical techniques used in medical diagnosis, food testing, and environmental monitoring.

Browse 215 market data Tables and 96 Figures spread through 312 Pages and in-depth TOC on "Immunoassay Market Size, Share & Trends Estimation Report By Outlook, By Region, And Segment Forecasts, 2022 - 2030" View detailed Table of Content here-https://www.contrivedatuminsights.com/product-report/immunoassay-market-248712/

The growth of the immunoassay market is driven by factors such as the increasing prevalence of chronic and infectious diseases, the rising demand for point-of-care testing, and the development of high-sensitivity immunoassay technologies. The COVID-19 pandemic has also contributed to the growth of the market, as immunoassays are widely used for the diagnosis and monitoring of the disease.

Market Dynamics

The rising prevalence of diseases such as cancer, diabetes, and cardiovascular diseases has led to an increased demand for immunoassays as a diagnostic tool. The growing incidence of infectious diseases, including COVID-19, has also contributed to the growth of the market. There is a growing demand for point-of-care testing, which provides rapid results and helps to improve patient outcomes. Immunoassays are widely used in point-of-care testing as they are easy to use and provide accurate results.

Immunoassay tests can be expensive, which may limit their use in certain regions or by certain populations. Immunoassay tests require skilled professionals to perform and interpret the results. A shortage of trained professionals could limit the adoption of immunoassay technology.

Alternative technologies, such as molecular diagnostics and next-generation sequencing, may compete with immunoassays for diagnostic and research applications.

The lack of standardization of immunoassay methods can lead to variability in results between different labs and assays. This can make it difficult to compare results and can limit the clinical utility of immunoassays. The preparation of biological samples for immunoassay testing can be challenging, as different sample types may require different preparation methods. Inadequate sample preparation can lead to inaccurate results.

Regional Analysis

Emerging markets in Asia, Latin America, and Africa offer significant opportunities for the growth of the immunoassay market. These regions have large populations and a growing incidence of chronic and infectious diseases, which are driving demand for diagnostic tests. The growing demand for point-of-care testing presents a significant opportunity for the immunoassay market. Point-of-care tests are easy to use, provide rapid results, and can be used in a variety of settings, including hospitals, clinics, and community health centers. RIA is an immunoassay technique that uses a radioactive label to detect and quantify specific biomolecules. RIA has been largely replaced by other immunoassay techniques due to concerns about radiation exposure.

FIA is an immunoassay technique that uses a fluorescent label to detect and quantify specific biomolecules. FIA is highly sensitive and can be used to detect very low levels of analytes. Multiplexed immunoassays allow for the simultaneous detection and quantification of multiple analytes in a single sample. This technique is used in a variety of applications, including biomarker discovery, drug discovery, and diagnostic testing. Other immunoassay techniques include turbidimetric immunoassay, immunofluorescence assay, and lateral flow assay.

Cardiology for the diagnosis and monitoring of various cardiac biomarkers such as troponin and BNP. The use of immunoassays in cardiology is growing rapidly due to their high sensitivity and specificity. Autoimmune Diseases diagnosis and monitoring of autoimmune diseases such as rheumatoid arthritis, lupus, and others. The use of immunoassays in autoimmune diseases is growing rapidly due to their ability to detect specific autoantibodies.

Allergy Testing detect specific IgE antibodies against allergens. This application segment includes the diagnosis and monitoring of various types of allergies such as food allergies, environmental allergies, and others. Drug Testing detect the presence of drugs or their metabolites in urine or blood samples. This application segment includes drug testing in various industries such as healthcare, sports, and others.

Latin America is expected to witness moderate growth in the immunoassay market due to the increasing prevalence of chronic diseases, growing healthcare expenditure, and increasing awareness about the benefits of early diagnosis.

The Middle East & Africa region is expected to witness steady growth in the immunoassay market due to the increasing prevalence of infectious diseases and the growing demand for point-of-care testing. However, the market growth in this region may be limited due to the lack of healthcare infrastructure and resources in some countries.

Competitive Analysis

Siemens Healthineers is another major player in the immunoassay market, offering a comprehensive range of products and services for the diagnosis and monitoring of various diseases. The company's product portfolio includes ADVIA Centaur immunoassay systems, Dimension immunoassay systems, and others.

Abbott Laboratories is a global healthcare company that offers a wide range of products and services, including immunoassays for the diagnosis and monitoring of various diseases. The company's product portfolio includes ARCHITECT immunoassay systems, i-STAT immunoassay systems, and others.

Danaher Corporation is a diversified technology company that offers a wide range of products and services, including immunoassays for the diagnosis and monitoring of various diseases. The company's product portfolio includes Beckman Coulter immunoassay systems, Radiometer immunoassay systems, and others.

In January 2022, Roche Diagnostics announced its acquisition of long-read sequencing company Stratos Genomics, which will enhance Roche's diagnostic capabilities in the field of precision medicine.

In December 2021, Siemens Healthineers completed its acquisition of Varian Medical Systems, a leading provider of cancer care solutions, which will enable Siemens Healthineers to expand its offerings in oncology diagnostics and therapy.

In November 2021, bioMérieux SA completed its acquisition of BBI Group, a leading provider of diagnostic tests and reagents, which will enable bioMérieux to expand its product portfolio and geographic presence.

In August 2021, Danaher Corporation announced its acquisition of Aldevron, a leading provider of plasmid DNA, mRNA, and proteins for the biotech industry, which will strengthen Danaher's position in the life sciences market.

In May 2021, Abbott Laboratories completed its acquisition of Veritor, a provider of rapid diagnostic tests, which will enable Abbott to expand its offerings in point-of-care testing and increase its global footprint.

Segmentation Analysis of The Global Immunoassay Market 2022-2030

The report forecasts revenue growth at global, regional, and country matrics and analyzes the latest industry trends in each of the sub-segments ranging from 2016-2030. For this, CDI has segmented the global Immunoassay market report based on capacity, vehicle, application, and propulsion type along with regional analysis. 

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagents & Kits
• ELISA Reagents & Kits    
• Rapid Test Reagents & Kits          
• ELISPOT Reagents & Kits              
• Western Blot Reagents & Kits    
• Other Reagents & Kits  

Analyzers/Instruments

• Open Ended Systems
• Closed Ended Systems
• Software & Services

Specimen Outlook (Revenue, USD Million, 2018 - 2030)

• Blood  
• Saliva    
• Urine    
• Other Specimens      

Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Radioimmunoassay (RIA)
• Enzyme Immunoassays (EIA)Rapid Test
• Chemiluminescence Immunoassays (CLIA)
• Fluorescence Immunoassays (FIA)
• Others

Application Outlook (Revenue, USD Million, 2018 - 2030)

• Therapeutic Drug Monitoring
• Oncology
• Cardiology
• Endocrinology
• Infectious Disease Testing
• Autoimmune Diseases
• Others

End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals
• Blood Banks
• Clinical Laboratories
• Pharmaceutical and Biotech Companies
• Academic Research Centers
• Others

Regional Outlook (Revenue, USD Million, 2022 - 2030)

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America